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Hepatitis A virus (HAV) is responsible for ~1.4 million new infections 
each year worldwide.[1-3] Transmission of HAV is via the faecal-
oral route, either through an infectious person or by ingestion 
of contaminated food or water.[4-6] Risk factors for infection with 
HAV include low socioeconomic status, larger household size and 
overcrowding, particularly in rural areas, limited access to clean water 
sources and inadequate sanitation facilities.[1,7]
Globally, the epidemiology of hepatitis A is changing owing 
to improved sanitation and living standards in some regions.[8,9] 
A decrease in HAV prevalence has been noted in modern urban 
populations, whereas in populations with poor or no sanitation and 
overcrowded living conditions, infection occurs at an early age. In 
this context, close to 100% of children acquire infection in the first 
decade of life.[8]
In the past, it was thought that South Africa (SA) was highly 
endemic for HAV infection. However, significant improvements in 
water sources and sanitation facilities over the past 2 decades may 
have had a significant effect on the epidemiology of the disease, 
and the country could be in an epidemiological transition. SA may 
therefore qualify for introduction of hepatitis A vaccine as per 
the World Health Organization (WHO) position paper,[10] which 
recommends vaccination for children ≥1 year of age in countries of 
intermediate or low endemicity.
Objectives
To investigate whether SA is experiencing an epidemiological 
transition from high to low hepatitis A endemicity.
Methods
We chose Western Cape Province (WCP) as a study site for 
convenience, and conducted an observational cross-sectional study 
to examine the seroprevalence of hepatitis A in children between 
1 and 7 years of age. Serum samples sent for routine haematology, 
chemistry and virology diagnostic testing were collected from three 
referral laboratories in the province, and were tested for antibodies 
against HAV. The study population was stratified into three age 
groups: 1 - 2 years, 3 - 4 years and 5 - 7 years.
We also conducted a retrospective review of hepatitis A laboratory 
results from two sources: hepatitis A immunoglobulin G (IgG) age-
specific prevalence from routine diagnostic samples submitted to the 
Groote Schuur Hospital (GSH) National Health Laboratory Service 
(NHLS) virology laboratory from 2009 to 2014, and surveillance data 
on acute HAV infections in WCP between 2009 and 2014 collected 
by the National Institute for Communicable Diseases (NICD). 
The hepatitis A IgG data included individuals who were being 
screened for hepatitis A immunisation status, e.g. children who were 
vaccinated and awaiting liver transplants.
Seroprevalence study
Routine specimens from 1 - 7-year-old patients resident in WCP 
and collected during the period August - October 2015 from 
primary- and tertiary-level healthcare facilities in the province were 
used for the study. Based on an expected prevalence of ~50% in the 
study population and a margin of error of 5% (0.05), a sample size 
of 384 was deemed sufficient.[11,12] Samples from patients with liver 
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disease were excluded, and the HIV status of the patients was not 
known. We decided to use the 482 specimens available for testing to 
accommodate for any potential equivocal results. Hepatitis A total 
antibody testing was performed at the NHLS diagnostic virology 
laboratory at GSH.
The following demographic details on the patients from whom the 
serum samples were obtained were also collected: age, gender, and 
residential location or referring clinics. It was not necessary to obtain 
informed consent, as there was no direct contact with the patients 
and the results of the study did not affect patient treatment.
Procedure
Samples were retrieved from the –80°C freezer and thawed at room 
temperature. Testing was performed according to the manufacturer’s 
instructions.[13] Serum samples were tested for anti-HAV total 
antibodies (IgG and immunoglobulin M (IgM)) using a manual 
enzyme immunoassay (Siemens Enzygnost anti-HAV), as per 
Siemens protocol.[13]
Test samples with equivocal results were retested in duplicate, 
and the remaining samples were stored at –80ºC. Anti-HAV total 
antibody results were entered on an Excel spreadsheet version 15.31 
(Microsoft, USA) and stored on an access-controlled computer 
located at the NHLS virology laboratory at GSH.
Retrospective review
• Routinely collected hepatitis A anti-IgG antibody test results were 
extracted from the GSH NHLS database from January 2009 to 
December 2014. These results were analysed to provide a retrospec-
tive review of hepatitis A seroprevalence during that period.
• Acute hepatitis A surveillance data (anti-HAV IgM antibody 
results) routinely collected from public sector hospitals and 
clinics in WCP by the NICD between 2009 and 2014 were also 
analysed.
No patient identifiers were available from the routinely reported 
data that we used for our retrospective review analysis. Only basic 
demographic data for these samples are therefore reported.
Data analysis
All data were first entered on an Excel spreadsheet version 15.3 
(Microsoft, USA) and stored on an access-controlled computer at 
Groote Schuur Hospital (NHLS server). Equivocal test results were 
excluded from analysis. SPSS version 23 (IBM, USA) was used for 
all the analysis. Descriptive statistics were generated from the cross-
sectional seroprevalence data, the GSH NHLS laboratory database 
(anti-HAV IgG results, January 2009 - December 2014) and the 
hepatitis A surveillance data provided by the NICD (anti-HAV IgM 
results, 2009 - 2014).
For both the NHLS and NICD data sets, we evaluated the hepatitis A 
trends from 2009 to 2014.
Ethical considerations
Ethics approval was obtained from the University of Cape Town 
Human Research Ethics Committee (ref. no. HREC/REF:227/2015) 
and the Stellenbosch University Human Research Ethics Committee 
(for samples collected from Tygerberg Hospital) (ref. no. S15/08/173). 
Permission to conduct a study using samples from Red Cross War 
Memorial Children’s Hospital (RCWMCH) was also obtained.
Results
Seroprevalence study
One serum sample test was equivocal (male, age 1 year) and 
remained equivocal even on repeat testing in duplicate. This sample 
was excluded from analysis, so only 481 samples were analysed. 
Seroprevalence, defined as the proportion of the serum samples that 
tested positive for anti-HAV total antibodies, was 44.1% (212/481). 
As expected, seroprevalence increased with age: 22.2% (45/203) for 
1 - 2-year-old children, 51.7% (31/60) for 3 - 4-year-old children 
and 62.4% (136/218) for 5 - 7-year-old children. Of the total samples 
tested, 231/481 (47.9%) were from females (Table 1).
Positive and negative results as well as the median age distribution 
for the 482 tested samples are shown in Fig. 1. 
Retrospective study
Hepatitis A seroprevalence from the NHLS GSH laboratory 
database, 2009 - 2014
We analysed and displayed the NHLS data from GSH as a heat map 
(Fig. 2). The total numbers of samples tested for the years 2009 - 
2014 were 2 456, 2 207, 2 182, 2 287, 2 244 and 2 318, respectively. 
Seroprevalence is displayed for the following age categories: 1 - 
2  years, 3 - 4 years, 5 - 7 years, 8 - 10 years, 11 - 15 years, 16 - 
20  years, 21 - 25 years, 26 - 30 years, 31 - 35 years, 36 - 40 years 
and >40 years. A three-colour scale was used: purple to white to 
green to indicate increasing seroprevalence, with the minimum 
(lowest value) purple, the midpoint (50th percentile) white and the 
maximum (highest value) green. Seropositive percentages <50% are 
displayed in white font, as are percentages ≥90%. A seroprevalence 
of ≥50% by age 15  years, but <90% by age 10 years, was noted in all 
years (intermediate endemicity as defined by the WHO), with the 
exception of 2010, where the seroprevalence in the 16 - 20-year age 
group was 93%. Of note, seroprevalence was consistently <90% under 
the age of 10 for all calendar years. This finding suggests that hepatitis 
A infection is not as endemic in this population as it is thought to be.
Review of acute hepatitis A surveillance data from WCP, 2009 - 2014
The results analysed and displayed in Fig. 3 are a summary of the 
Table 1. Participant gender, age groups and anti-HAV total antibody results
Age groups (years)
Total1 - 2 3 - 4 5 - 7
Gender,* n (%)
Female 91 (44.8) 36 (60) 104 (47.7) 231 (48.0)
Male 112 (55.2) 24 (40) 114 (52.3) 250 (52.0)
Total 203 (42.2) 60 (12.5) 218 (45.3) 481 (100)
Results, n (%)
Negative 158 (77.8) 29 (48.3) 82 (37.6) 269 (55.9)
Positive 45 (22.2) 31 (51.7) 136 (62.4) 212 (44.1)
HAV = hepatitis A virus.
*Fisher’s exact test showed no significant statistical difference between males and females.
316       May 2019, Vol. 109, No. 5
RESEARCH
surveillance data provided by the NICD, and reflect hepatitis A 
IgM-positive tests from 2009 to 2014. The total numbers of results 
analysed per year for the years 2009 - 2014 were 475, 637, 711, 526, 
656 and 879, respectively, showing a peak of positivity around the 
age of 6 years.
The positive hepatitis A IgM results that were recorded from hospitals 
in WCP from 2009 to 2014, provided by the NICD, are also displayed 
in Fig. 4. We grouped the results into three categories: 1 - 6 years, 7 - 
40 years and >40 years, and plotted them according to each calendar 
year. In the past most children in SA were infected with HAV by age 
6 years, hence the reason for the selection of 1 - 6-year-old category, 
and we wanted to assess whether this has shifted to the 7 - 40-year age 
group, as well as to assess the burden of disease in the >40-year-old 
age group. Across all years, the highest number of clinical hepatitis 
A cases was in the 7 - 40-year age group. Cases in the >40-year age 
group were very few, accounting for only 4.2% of the total positives 
in 2009, 2.5% in 2010, 3% in 2011, 6.5% in 2012, 3.4% in 2013 and 
4.7% in 2014.
Discussion 
Our cross-sectional study, for which the samples were collected 
between August and October 2015, indicates a seroprevalence of 
44.1% in the 1 - 7-year age group. The retrospective study using the 
NHLS GSH data also reflects intermediate endemicity, while analysis 
of the NICD data displays an increase in symptomatic hepatitis A 
infection in all groups, but mostly in the 7 - 40-year age group. Taken 
together, the results indicate a possible epidemiological change of 
HAV infection in WCP. We propose that better-designed studies be 
prioritised in the future to generate quality data that can guide the 
development of a vaccination policy against HAV infection in SA.
According to a WHO position paper on hepatitis A vaccines,[10] 
seroprevalence levels of endemicity are classified as follows: high 
(≥90% by age 10 years), intermediate (≥50% by age 15 years, with 
<90% by age 10), low (≥50% by age 30 years, with <50% by age 15) 
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Fig. 1. Median age distribution of anti-HAV total antibody-positive and 
negative individuals. The box plot demonstrates the negative and positive 
results, as well as the median age distribution of the 482 tested samples. 
The median age of positivity in the sample population was ~4 years, and no 
statistical difference was noted between the positive and negative samples at 
this age. (HAV = hepatitis A virus.)
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Fig. 2. Heat map of the positive NHLS GSH hepatitis A IgG results, 2009 - 2014. The total numbers of samples tested in the years 2009 - 2014 were 2 456, 
2 207, 2 182, 2 287, 2 244 and 2 318, respectively. Pearson’s χ2 test showed no statistical difference between samples tested per year. The positive hepatitis A IgG 
results that were extracted from the GSH NHLS database (Disa*Lab) from 2009 to 2014 are reflected as percentages and stratified into the following groups: 
1 - 2 years, 3 - 4 years, 5 - 7 years, 8 - 10 years, 11 - 15 years, 16 - 20 years, 21 - 25 years, 26 - 30 years, 31 - 35 years, 36 - 40 years and >40 years. A three-
colour scale was used (purple to white to green), with minimum (lowest value) purple, midpoint (50th percentile) white, and maximum (highest value) green. 
Seropositive percentages <50% are displayed in white font, as well as percentages ≥90%. Of note that is that the seroprevalence is <90% by age 10 from 2009 
to 2014. (NHLS = National Health Laboratory Service; GSH = Groote Schuur Hospital; IgG = immunoglobulin G.)
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to be highly endemic for hepatitis A, as it 
is thought that most children are exposed 
to the virus by the age of 6 years.[4,14] Our 
cross-sectional data showed a seroprevalence 
of 44% among 1 - 7-year-olds. The moderate 
seroprevalence observed in our study differs 
from the high seroprevalence (almost 100%) 
reflected in the studies done in the past.[4,14] 
However, the study populations in our study 
and past studies are not directly comparable. 
For example, Abdool Karim and Coutsoudis[14] 
looked at seroprevalence in Durban, limited 
to the black urban population from newborn 
to 13 years of age, and the results showed that 
the seroprevalence in this age group in SA was 
almost 100% (by age 6 years).
Our results indicating a possibility of 
intermediate HAV endemicity in WCP could 
be explained by two factors. Firstly, there has 
been a marked improvement in water sources 
and sanitation facilities in SA.[15,16] Secondly, 
there has been socioeconomic development in 
resource-poor regions, with improved hygiene. 
Together these factors may lead to change from 
a high to an intermediate HAV endemicity 
pattern, a change known as ‘epidemiological 
transition’.[17] Hepatitis A is enterically trans-
mitted, and as hygiene improves, children can 
be expected to be exposed less frequently, and 
acquire infection at a later age. Seroprevalence, 
which reflects past infection, therefore declines 
in young children.
We were not privy to the socioeconomic 
status of the subjects tested or their access to 
clean water sources. However, our selected 
population may well be representative of an 
‘average SA household’. In 1990 only 38% 
of the rural population in SA had access to 
sanitation facilities, and this figure improved 
to 61% by 2015.[16] In contrast, 64% of the 
urban population had access to sanitation 
facilities in 1990, increasing to 70% by 2015. 
Access to clean water has improved: in 1990, 
66% of the rural population had access to 
water sources, increasing to 81% by 2015.[15]
The NHLS data from GSH reflected 
seroprevalence of <90% by age 10, indicating 
intermediate endemicity from as early as 
2009 as per the WHO epidemiological 
definitions. There was minimal variation 
through all the age groups from 2009 to 
2014. Our analysis of the NICD data on 
acute HAV infections revealed an increased 
number of symptomatic infections in the 
7 - 40-year group; however, the peak age 
of symptomatic infection is seen at 6 years.
A similar trend was noted in a recent 



















Fig. 3. Age distribution of the NICD WCP hepatitis A surveillance data (absolute numbers). The 
positive hepatitis A IgM results collected from WCP clinics and hospitals were provided by the NICD, 
and show a peak of positivity at age 6 years. (NICD = National Institute for Communicable Diseases; 
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Fig. 4. NICD hepatitis A IgM WCP surveillance data. These are results collected by the NICD from various clinics and hospitals in WCP. The results are 
displayed as absolute numbers of positive tests and not percentages, as the total number of tested samples per age group (positive and negative) was not 
available. We grouped the results from the patients into three groups: 1 - 6 years, 7 - 40 years and >40 years. Cases in the >40-year age group across all years 
were very few. The highest number of clinical hepatitis A cases was in the 7 - 40-year age group from 2009 to 2014. Also, and worryingly, for the period 
between 2009 and 2014, increasing numbers of cases of hepatitis A acute infection were observed among children aged 1 - 6 years. (NICD = National Institute 
for Communicable Diseases; WCP = Western Cape Province; IgM = immunoglobulin M; HAV = hepatitis A virus.)
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lence in the Middle East and North Africa region (MENA). [18] One 
of the studies mentioned in this review was conducted in Saudi 
Arabia and demonstrated a decline in HAV prevalence reported 
among Saudi children and adolescents over a 20-year period, from 
52% in 1989 to 25% in 1997 and 18.6% in 2008.[19] In another 
study, Memish et al.[20] looked at trends in Saudi Arabia from 2000 
to 2007, and reported 20 - 30% declining trends. HAV incidence 
decreased by 42% in <15-year-olds and increased by 61% in 
>15-year-olds. Another study mentioned in the systematic review 
looking at seroprevalence in MENA countries was conducted in 
Tunisia (2000 - 2007), where the prevalence was documented as 
follows: 91.9% and 80.6% in 2000 and 2007, respectively, among 
18 - 20-year-olds, v. 99% and 92% in adults >26 years of age.[21] This 
study highlighted the susceptibility of adolescents and young adults 
to HAV. Recent epidemiological studies in India have also shown a 
decline in hepatitis A seroprevalence among younger children and 
an increasing susceptibility in older children and young adults,[22] a 
trend we observed in our study.
A possible explanation for the higher seroprevalence in the NHLS 
data from GSH as opposed to our cross-sectional study could be 
selection bias. The NHLS data included results from individuals who 
were being screened for hepatitis A immunisation status, for example 
children who were vaccinated and awaiting liver transplants. This 
could have inflated the seroprevalence in this age group. Nonetheless, 
the NHLS data also revealed that the seroprevalence was <90% by age 
10 and ≥50% by age 15 from 2009 to 2014, which fits the definition of 
intermediate endemicity as defined by the WHO.[10]
The observed increase in average age of infection is a concern 
because it is associated with increased morbidity and mortality due to 
hepatitis A.[17,18,23] For this reason, the WHO recommends integration 
of the hepatitis A vaccine into the national immunisation schedule 
for children ≥1 year of age in countries of intermediate or low 
endemicity. Hepatitis A vaccine is expensive, and its routine use in 
areas of high endemicity is not cost-effective.[10] Our cross-sectional 
study showed that >50% of children are already infected with HAV 
by the age of 4 years. Vaccination against HAV would therefore be 
beneficial before the age of 2 years in a setting such as WCP. We 
hypothesise that there will be significant public health benefits in 
providing routine vaccination against HAV to under-2-year-olds via 
the Expanded Programme on Immunisation in South Africa.
Study limitations
There were limitations to our study, particularly with regard to 
the retrospective NHLS data and the NICD surveillance data. The 
retrospective data only included samples that were sent to the 
laboratory for testing, and therefore do not represent the population 
as a whole. Many of the patients whose serostatus was reflected in the 
retrospective data were also being actively screened for viral hepatitis. 
The results from the current study also only include samples sent to 
the laboratory for routine testing from an urban setting in WCP, and 
therefore do not represent the population as a whole. The samples 
that were tested for hepatitis A total antibodies only represent the 
public sector in SA, as we did not obtain samples from the private 
laboratories. We also did not have data regarding the socioeconomic 
conditions of the patients whose sera were used. More studies need 
to be conducted, especially in the rural areas.
Conclusions
The results obtained from the current study reflect a hepatitis A 
seroprevalence of 44% in the 1 - 7-year-old population. The NHLS 
data reflect intermediate endemicity from 2009 to 2014. The NICD 
surveillance data indicate that most of the symptomatic hepatitis A 
infections occurred in the 7 - 40-year age group in WCP. This pilot 
study highlights the need for further studies to determine whether a 
change in the hepatitis A vaccination policy is required. These studies 
should be extended to the rest of the country, including rural areas.
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